View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 2, 2021

Astellas and Dyno Therapeutics to develop AAV gene therapy vectors

Dyno will design the new AAV capsids with improved functional properties for gene therapy.

Astellas Pharma has signed an option and licence agreement with Dyno Therapeutics to develop next-generation adeno-associated virus (AAV) gene therapy vectors for skeletal and cardiac muscle.

The gene therapy vectors will be developed using Dyno Therapeutics’ CapsidMap platform, which uses artificial intelligence (AI) to rapidly optimise AAV capsids for delivery across multiple organs.

According to the deal, Dyno Therapeutics will be responsible for designing the new AAV capsids with improved functional properties for gene therapy.

Astellas will conduct preclinical, clinical and marketing activities and also produce gene therapy product candidates using the capsids.

Astellas chief business officer, chief financial officer and chief strategy officer Naoki Okamura said “Through our efforts in gene therapy and the Astellas Gene Therapies Center of Excellence, Astellas strives to identify, develop and deliver transformative gene-based therapies for patients with genetic diseases who currently have few or no effective treatment options.

“Our principal focus is on developing adeno-associated virus delivered therapies for the treatment of well-defined serious diseases.

“We are dedicated to delivering novel approaches and utilising new technologies that can deliver transformational value for patients.”

According to the agreement, the company will make an upfront payment of $18m to Dyno Therapeutics, which will also be eligible for additional milestone and royalty payments estimated to be more than $1.6bn in total value.

Last year, Astellas acquired Audentes Therapeutics and established the Astellas Gene Therapies Center of Excellence.

The company noted that the new partnership combines Astellas Gene Therapies’ global leadership in AAV-based pipeline assets with Dyno Therapeutics’ AAV vector engineering capabilities powered by AI.

In August, Astellas and Minovia Therapeutics signed a global strategic partnership and licence agreement for the research, development and commercialisation of new cell therapy programmes for mitochondrial dysfunction-driven diseases.

Cell & Gene Therapy Coverage on Pharmaceutical Technology supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology